Beacon Pharmaceuticals PLC (DSE:BEACONPHAR)

Market Cap	26.57B
Revenue (ttm)	11.58B
Net Income (ttm)	570.05M
Shares Out	231.00M
EPS (ttm)	2.47
PE Ratio	46.60
Forward PE	n/a
Dividend	2.00 (1.74%)
Ex-Dividend Date	Oct 28, 2024

Volume	620,128
Average Volume	187,421
Open	110.80
Previous Close	109.40
Day's Range	110.30 - 115.70
52-Week Range	92.40 - 152.10
Beta	-0.56
RSI	56.80
Earnings Date	Oct 29, 2025

About Beacon Pharmaceuticals

Beacon Pharmaceuticals PLC engages in the producing and promoting of pharmaceuticals finished formulations, lifesaving intravenous fluids, active pharmaceutical ingredients, bio-tech products, and genetic engineering products in Bangladesh and internationally. The company offers general, oncology, biotech, and chronic care products. It also provides products in various therapeutic categories that include oncology, hematology, hepatology, nephrology, antibiotics, analgesics, anti-diabetics, respiratory, cardiovascular, dermatology, gastrointesti...

• Industry: Pharmaceutical Preparations
• Founded: 2001
• Employees: 4,162
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: BEACONPHAR

Financial Performance

In 2024, Beacon Pharmaceuticals's revenue was 10.70 billion, an increase of 25.76% compared to the previous year's 8.51 billion. Earnings were 521.01 million, an increase of 2.19%.